VEMAKD: Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Sponsor

University of Alabama at Birmingham (Other)

Overall Status

Completed

CT.gov ID

NCT02497300

Collaborator

National Institutes of Health (NIH) (NIH)

Enrollment

Location

Arms

Actual Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Vascular endothelial dysfunction increases cardiovascular (CV) risk and contributes to the progression of chronic kidney disease (CKD). Mineralocorticoid receptor (MR) antagonists have been shown to improve endothelial function, as well as decrease CV mortality and proteinuria. The specific biochemical pathways that produce these pharmacological effects for MR antagonists, however, are poorly understood. This study investigates the effect of MR antagonism on endothelial function in patients with moderate (stage III) CKD using a randomized, controlled trial. Three specific aims are proposed: Aim 1: To determine if spironolactone improves endothelial function as compared to amiloride in patients with stage III CKD; Aim 2: To determine if oxidative stress is associated with changes in endothelial function by spironolactone compared to amiloride in patients with stage III CKD; and Aim 3: To determine if endothelial dysfunction contributes to albuminuria in patients with stage III CKD. The clinical relevance is to improve understanding of the mechanisms of kidney function decline in CKD in order to develop interventions to delay or prevent dialysis, which would translate into alleviating patient suffering, caregiver burden, and health care costs.

Condition or Disease	Intervention/Treatment	Phase
Chronic Kidney Disease Albuminuria	Drug: Spironolactone Drug: Amiloride	Phase 2

Detailed Description

Study participants with proteinuric, stage III CKD will be randomly assigned in a double-masked fashion to spironolactone 25mg daily or amiloride 5 mg daily for 6 weeks and then crossed over to the alternate study medication after a 1 month wash-out period. Vascular function will be assessed at baseline and the end of each 6 week treatment period by: 1) ultrasound guided flow-mediated dilation (FMD) of the brachial artery, 2) impedence cardiography, 3) pulse-wave velocity, 4) 24 hour ambulatory blood pressure monitoring, and 5) serum and urine biomarkers. Participants will undergo a total of 7 visits over 16-18 weeks; 3 of the 7 visits will involve vascular function testing.

A study visit where vascular function testing is to be performed will begin at 0800 in the morning and start with a vital sign assessment including height, weight, body fat percent, and left arm automated BP measurement followed by confirmation of fasting status and a brief past medical history. Each participant will then lie supine for 10 minutes in preparation for vascular function testing. Following the pulse wave velocity, impedence cardiography, and FMD measurements, the participant will have his/her blood and urine collected for laboratory testing. Laboratory testing will include ~20 mL of blood for plasma and serum testing. Participants will return 24 hour urine samples and have a 24 hour ambulatory monitor placed. This entire visit is expected to take 2 hours.

Study visits where vascular function testing will not be performed (e.g., screening visit, visit 2, visit 4, and visit 5; should last 30 minutes and involve a medication assessment, vital sign check, and blood collection for serum potassium (~4 mL of blood).

All study medication will be prepared by the the University of Alabama (UAB) Research Pharmacy in matching capsules and placed in pill bottles labeled "A" and "B". The order of medication dispensing will follow simple randomization using an a priori randomization list prepared by the research pharmacy. All study personnel with participant interaction are masked to the order of study medication.

Study Design

Study Type:

Interventional

Actual Enrollment :

21 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Actual Study Start Date :

Mar 1, 2015

Actual Primary Completion Date :

Jul 1, 2021

Actual Study Completion Date :

Jul 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Spironolactone Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.	Drug: Spironolactone
Active Comparator: Amiloride Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.	Drug: Amiloride

Arm

Intervention/Treatment

Experimental: Spironolactone

Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.

Drug: Spironolactone

Active Comparator: Amiloride

Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.

Drug: Amiloride

Outcome Measures

Primary Outcome Measures

Percent change in flow-mediated dilation [6 weeks]
Difference in percent change of ultrasound-guided flow-mediated dilation between 6 weeks of spironolactone vs. 6 weeks of amiloride.
Change in oxidative stress as measured by urine levels of F2-isoprostanes [6 weeks]
Difference in level of reduction in urine 8-iso-prostaglandin-F2-alpha per mg of creatinine levels between 6 weeks of spironolactone vs. 6 weeks of amiloride. Changes in FMD will be modeled with changes in F2-isoprostane levels using a general linear model with adjustment for as many as 3 covariates, one of which being treatment group.
Change in albuminuria [6 weeks]
Difference in the change of the urine albumin-to-creatinine ratio after 6 weeks of spironolactone vs. 6 weeks of amiloride.

Secondary Outcome Measures

Change in serum potassium [6 weeks]
Difference in the change in serum potassium levels after 6 weeks of spironolactone vs. 6 weeks of amiloride.
Change in estimated glomerular filtration rate [6 weeks]
Difference in the change in estimated glomerular filtration rate by 4 variable Modification of Diet in Renal Disease (MDRD) study equation after 6 weeks of spironolactone vs. 6 weeks of amiloride.

Other Outcome Measures

Correlation between change in plasma asymmetric dimethylarginine levels and change in flow-mediated dilation [6 weeks]
Changes in FMD will be modeled with changes in plasma asymmetric dimethylarginine levels using a general linear model with adjustment for as many as 3 covariates, one of which being treatment group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adults (18-65 years of age)
CKD (eGFR 25-60 mL/min/1.73m2) with urine albumin-to-creatinine ratio > 30 mg/g
CKD (eGFR > 60 mL/min/1.73m2) with urine albumin-to-creatinine ratio ≥ 300 mg/g

Exclusion Criteria:

Severe hypertension (HTN) (office BP ≥ 160/100 mm Hg)
Hypotension (office BP < 110/70 mm Hg)
Serum potassium > 5 milliequivalent/L
History of arrhythmia, including atrial fibrillation
Pregnant or breast feeding woman
Diabetes mellitus (DM) type 1
Diabetes mellitus type 2 with glycosylated hemoglobin ≥ 6.5%
Dementia or cognitive impairment prohibiting consent
History of ischemic stroke, unstable angina, or myocardial infarction within the past 6 months
Allergy or intolerance to spironolactone or amiloride
Use of an MR antagonist or an epithelial sodium channel blocking medication within the last month
Known primary aldosteronism or renal artery stenosis